ShareValue scores for 003220.KO: Valuation 58, Quality 39, Growth 46, Health 45.

003220.KO
KRX

Daewon Pharmaceutical Co. Ltd.

₩8,160.00(+4.75%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

6% to 17%
Valuation
58
Fair Value
Price vs Value
Quality
39
Weak
Business Strength
Growth
46
Moderate
Revenue & Earnings
Health
45
Moderate
Financial Stability
Momentum
26
Bearish
Price Trend

Company Details

About

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026